The role of triglycerides in cardiovascular risk

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 505-511

  Gandotra, Puneet ^b   Miller, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYLOMICRON; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; RIMONABANT; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXERCISE; FLUSHING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREVALENCE; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLOFIBRIC ACID; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; NIACIN; RISK FACTORS; TRIGLYCERIDES;

EID: 58249093993     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0079-0     Document Type: Article

References (56)

1. Lowering Blood Cholesterol to Prevent Heart Disease. NIH Consensus Statement Online [no authors listed]. 1984, 5:1-11. Available at http://consensus.nih.gov/1984/1984Cholesterol047html.htm. Accessed July 29, 2008.
2. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute, NIH; NIH Publication No. 93-3095; 1993.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
4. Pocock SJ, Shaper AG, Phillips AN: Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ 1989, 298:998-1002.
5. Wilson PW, Anderson KM, Castelli WP: Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham offspring study. Am J Med 1991, 90:11-16.
6. Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992, 152:28-34.
7. Cullen P, von Eckardstein A, Assmann G: Genetic and acquired abnormalities of lipoprotein metabolism. Cardiovasc Risk Factors 1996, 6:99-121.
8. Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000, 86:943-949.
9. Hegele RA: MonogeniW dyslipidemias: window on determinants of plasma lipoproteins metabolism. Am J Hum Genet 2001, 69:1161-1171.
10. Austin MA, McKnight B, Edwards KL, et al.: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000, 101:2777-2782.
11. Yuan G, Al-ShaliIKZ, Hegele RA: Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2000, 176:1113-1120.
12. Walden CC, Hegele RA: Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994, 120:1026-1036.
13. Pollex RL, Hegele RA: Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006, 3:482-489.
14. Lemieux I: HypertriglyAeridemic waist: a marker of atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000, 102:179-184.
15. Pownall HJ: Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins. J Lipid Res 1994, 35:2105-2113.
16. Rimm EB, Williams P, Fosher K, et al.: Moderate alcohol intake and lower risk of heart disease: Meta analysis of effects on lipids and haemostatic factors. BMJ 1999, 319:1523-1528.
17. Miller M: Current perspectives on the management of hypertriglyceridemia. Am Heart J 2000, 140:232-240.
18. Rapp RJ: HypertrAglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev 2002, 10:163-172.
19. Lechleitner M, Hoppichler F, F̈er B, Patsch JR: Low-density lipoproteins of the post prandial state induce cellular cholesteryl ester accumulation in macrophages. Arterioscler Thromb 1994, 14:1799-1807.
20. Ooi EM, Barrett PH, Chan DC, Watts GF: Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008, 114:611-624.
21. Miller M, Ginsberg HN, Schaefer EJ: Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008, 101:1003-1008.
22. Imke C, Rodriguez BL, Grove JS, et al.: Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005, 25: 1718-1722.
23. Assmann G, Schulte H, Eckardstein AV: Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle aged men. Am J Cardiol 1996, 77:1179-1184.
24. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3: 213-219.
25. Miller M, Seidler A, Moalemi A, Pearson TA: Normal triglyceride levels and coronary artery disease events. The Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998, 31: 1252-1257.
26. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: An eight year follow up in the Copenhagen Male Study. Circulation 1998, 97: 1029-1036.
27. Patel A, Barzi F, Jamrozik K, et al.: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110: 2678-2686.
28. Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115: 450-458.
29. Tirosh A, Rudich A, Shochat T, et al.: Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007, 147: 377-385.
30. Miller M, Cannon CP, Murphy SA, et al.: Impact of triglyceride levels beyond low-density cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730.
31. U.S. Preventive Services Task Force: Screening for Lipid Disorders in Adults. Released date: June 2008. Available at http://www.ahrq.gov/ clinic/uspstf/uspschol.htm. Accessed May 2008.
32. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
33. Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
34. Miller M, Zhan M, Georgopoulos A: Effect of desirable fasting triglycerides on the postprandial response to dietary fat. J Investig Med 2003, 51: 50-55.
35. Brunzell JD, Albers JJ, Chait A: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983, 24: 147-155.
36. Otvos J: Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol 1999, 22(6 Suppl): II21-II27.
37. Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr 1992, 56: 320-328.
38. Brunzell JD: Clinical practice. Hypertriglyceridemia. N Engl J Med 2007, 357: 1009-1017.
39. Purnell JQ, Kahn SE, Albers JJ, et al.: Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000, 85: 977-982.
40. Centers for Disease Control and Prevention (CDC): Prevalence of physical activity, including lifestyle activities among adults-United States, 2000-2001. MMWR Morb Mortal Wkly Rep 2003, 52: 764-769.
41. Haskell WL, Lee IM, Pate RR, et al.: Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007, 116: 1081-1093.
42. Szapary PO, Bloedon LT, Foster GD: Physical activity and its effects on lipids. Curr Cardiol Rep 2003, 5: 488-492.
43. Lichtenstein AH, Appel LJ, Brands M, et al.: Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006, 26: 2186-2191.
44. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) study [no authors listed]. Circulation 2000, 102:21-27.
45. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in Helsinki Heart Study. Implications for treatment. Circulation 1992, 85: 37-45.
46. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.
47. Canner PL, Berrge KG, Wenger NK, et al.: Fifteen-year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986, 8: 1245-1255.
48. Stein EA, Lane M, Laskarazewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998, 81:B66-B69.
49. Grundy SM: ConsRnsus statement: role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol 1998, 81:B1-B6.
50. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. GISSI-Prevenzione Investigators [no authors listed]. Lancet 1999, 354:447-455.
51. Yokoyama M, Origasa H, Matsuzaki M, et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
52. Ginsberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99:56i-67i.
53. AIM-HIGH Clinical Study: Inclusion criteria and major exclusion criteria. Available at accelerator.axioresearch.com/aim-high/. Accessed June 12, 2008.
54. Clinical Trial Service Unit & Epidemiological Studies Unit: HPS2-THRIVE Press Release. Available at http://www.ctsu.ox.ac.uk/ pressreleases/2006-05-31/hps2-thrive-pressrelease. Accessed June 12, 2008.
55. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabanoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: A randomized controlled trial. JAMA 2006, 295:761-775.
56. Després JP, Golay A, Sjöström L, et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353: 2121-2134.